10-Q: Legacy Ventures International Reports Continued Losses in Q2 2025, Raising Going Concern Doubts

Legacy Ventures International's Q2 2025 report reveals ongoing losses and a working capital deficiency, casting significant doubt on the company's ability to continue as a going concern.

Summary

• Legacy Ventures International reported a net loss of $23,722 for the three months ended December 31, 2024, and $44,193 for the six months ended December 31, 2024.
• The company's operating expenses were $23,723 for the three months and $44,194 for the six months ended December 31, 2024, primarily due to professional fees.
• As of December 31, 2024, the company had a working capital deficiency of $181,062 and an accumulated deficit of $6,615,865.
• The company's ability to continue as a going concern is dependent on obtaining additional debt or equity financing and continued shareholder support.
• The company plans to engage in Biotech research & development and health care research & development through its wholly owned subsidiary in Hong Kong, Ever Green Living Ventures Ltd.

Sentiment

Score: 2

Explanation: The report paints a bleak picture of the company's financial health, with increasing losses, a significant working capital deficiency, and doubts about its ability to continue as a going concern. The ineffective disclosure controls further contribute to the negative sentiment.

Positives

• The company received $61,994 in advances from a shareholder, providing some financing for operations.
• Legacy Ventures International owns 100% of Ever Green Living Ventures Ltd, a company incorporated in Hong Kong, with plans to engage in Biotech research & development and health care research & development.

Negatives

• The company's net loss increased significantly compared to the previous year.
• The company has a substantial working capital deficiency and accumulated deficit.
• The company's disclosure controls and procedures are ineffective.
• The company's auditor, consultant, edgar agent and transfer agent fees are high.

Risks

• The company's ability to continue as a going concern is uncertain and dependent on securing additional financing.
• Failure to obtain additional funding could lead to the cessation of operations and loss of investment for shareholders.
• The company's internal controls over financial reporting are weak, increasing the risk of errors or fraud.
• The company's reliance on shareholder advances may not be sustainable in the long term.

Future Outlook

The company anticipates a net loss for the period ending December 31, 2024, and expresses substantial doubt about its ability to continue operations without additional cash inflows.

Management Comments

• The Company anticipates a net loss for the period ending December 31, 2024 and with the expected cash requirements for the coming months, without additional cash inflows from a corporate transaction or continuing financial support of the shareholders, there is substantial doubt as to the Company's ability to continue operations.
• Based upon this evaluation, the Company's chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures as of the end of the period covered by this Quarterly Report were ineffective due to a lack of segregation of duties, due to limited administrative and financial personnel and related resources and as the Company only has one director.

Industry Context

The company's plan to engage in Biotech research & development and health care research & development through its wholly owned subsidiary in Hong Kong places it in the competitive biotech and healthcare industries, which require significant capital investment and are subject to regulatory scrutiny.

Comparison to Industry Standards

• Given the lack of revenue and ongoing losses, Legacy Ventures International's financial performance is significantly below industry standards for biotech and healthcare companies.
• Comparable companies in the early stages of biotech or healthcare R&D typically have secured substantial funding through venture capital or other sources, which Legacy Ventures International appears to lack.
• The company's negative working capital and accumulated deficit are also indicative of financial distress compared to industry peers.

Related Party Transactions

• The company received advances from a shareholder and owes amounts to a director.

Stakeholder Impact

• Shareholders face the risk of losing their entire investment if the company ceases operations.
• The company's ability to execute its business plan and create value for stakeholders is uncertain.

Next Steps

• The company needs to secure additional debt or equity financing to continue operations.
• The company needs to improve its internal controls over financial reporting.
• The company needs to execute its operating plan for Biotech research & development and health care research & development through its wholly owned subsidiary in Hong Kong.

Key Dates

Keywords

financial statements, going concern, net loss, working capital deficiency, Legacy Ventures International, biotech, healthcare, research and development